These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 31435754

  • 21. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F, Salaffi F, Fornaro M, Di Carlo M, Gentileschi S, Cantarini L, Lopalco G.
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [Abstract] [Full Text] [Related]

  • 22. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT, Geborek P, Saxne T, Kapetanovic MC.
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [Abstract] [Full Text] [Related]

  • 23. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
    Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Wittig BM, Gnann H, Greger G, Tony HP, Burkhardt H.
    Scand J Rheumatol; 2019 Sep; 48(5):375-382. PubMed ID: 31311386
    [Abstract] [Full Text] [Related]

  • 24. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B.
    Joint Bone Spine; 2014 Jul; 81(4):352-9. PubMed ID: 24721422
    [Abstract] [Full Text] [Related]

  • 25. Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.
    Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR.
    PLoS One; 2014 Jul; 9(8):e105193. PubMed ID: 25141123
    [Abstract] [Full Text] [Related]

  • 26. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ.
    Clin Exp Rheumatol; 2017 Jul; 35(3):431-437. PubMed ID: 28079512
    [Abstract] [Full Text] [Related]

  • 27. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    Zhou M, Xu R, Kaelber DC, Gurney ME.
    PLoS One; 2020 Jul; 15(3):e0229819. PubMed ID: 32203525
    [Abstract] [Full Text] [Related]

  • 28. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B, Devauchelle A, Boyard PL, Sejourné A, Fardellone P, Goëb V.
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract] [Full Text] [Related]

  • 29. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC, Peris K, Berardesca E, Bianchi L, Richetta A, Bernardini N, De Simone C, Teoli M, Zangrilli A, D'epiro S, Orsini D, Narcisi A, Chimenti S, Costanzo A.
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [Abstract] [Full Text] [Related]

  • 30. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, Soubrier M, Avouac J, Brocq O, Sellam J, de Vries N, Huizinga TWJ, Jury EC, Manson JJ, Mauri C, Matucci A, Hacein Bey Abina S, Mulleman D, Pallardy M, Broët P, Mariette X, ABIRISK Consortium.
    JAMA Netw Open; 2023 Jul 03; 6(7):e2323098. PubMed ID: 37436748
    [Abstract] [Full Text] [Related]

  • 31. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, Escudero-Vilaplana V, Fernández-Fuente MA, Ferrit-Martin M, Gómez-Germá P, Martínez-Sesmero JM, Mayorga-Pérez J, Menchén-Viso B, Merino-Alonso J, Polache-Vengud J, Sánchez-Guerrero A.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jul 03; 15(5):851-8. PubMed ID: 25972066
    [Abstract] [Full Text] [Related]

  • 32. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Res Ther; 2018 Dec 13; 20(1):275. PubMed ID: 30545393
    [Abstract] [Full Text] [Related]

  • 33. Treatment persistence of biologics among patients with psoriatic arthritis.
    Haddad A, Gazitt T, Feldhamer I, Feld J, Cohen AD, Lavi I, Tatour F, Bergman I, Zisman D.
    Arthritis Res Ther; 2021 Jan 29; 23(1):44. PubMed ID: 33514410
    [Abstract] [Full Text] [Related]

  • 34. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
    Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, Pitsigavdaki S, Kalogiannaki E, Terizaki M, Bertsias G, Sidiropoulos P.
    Rheumatol Int; 2024 Feb 29; 44(2):249-261. PubMed ID: 37815625
    [Abstract] [Full Text] [Related]

  • 35. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.
    Semin Arthritis Rheum; 2017 Oct 29; 47(2):183-192. PubMed ID: 28413099
    [Abstract] [Full Text] [Related]

  • 36. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
    Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Res Ther; 2009 Oct 29; 11(2):R52. PubMed ID: 19356232
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr 29; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 38. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.
    Joint Bone Spine; 2012 Dec 29; 79(6):591-6. PubMed ID: 22480748
    [Abstract] [Full Text] [Related]

  • 39. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
    Iannone F, Lopriore S, Bucci R, Lopalco G, Chialà A, Cantarini L, Lapadula G.
    J Rheumatol; 2016 May 29; 43(5):911-7. PubMed ID: 26980583
    [Abstract] [Full Text] [Related]

  • 40. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Int J Rheum Dis; 2018 Nov 29; 21(11):1986-1992. PubMed ID: 30168265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.